<\/p>\n
The EBA Clinical Trials Subcommittee has analyzed the status and level of adaptation of Ukrainian clinical trial sites after a year of the rf’s full-scale war against Ukraine by conducting a survey among CT sites working with EBA CTS member companies.<\/span><\/span>\u00a0<\/span><\/span><\/p>\n The respondents are scattered throughout Ukraine, except for the temporarily occupied territories. The biggest share of CT sites that took part in the survey is located in the capital of Ukraine, Kyiv. These are 60 centers or 26%. Kharkiv is a close second, with 26 CT sites (13%) answering the survey. The third and fourth positions in terms of the number of respondents are occupied by Lviv (21 sites) and Ivano-Frankivsk (18 sites) regions. We also received 15 responses each from Zaporizhzhia and Dnipro. All other sites are almost evenly distributed across the country’s regions. A total of 227 centers participated in the survey.<\/span><\/span>\u00a0<\/span><\/span><\/p>\n In addition to the vast geography of the centers\u2019 location, the therapeutic areas of CTs conducted at the centers are also diverse.\u00a0 Most clinical trials are<\/span><\/span>\/<\/span>were being conducted by respondents in the following areas: Cardiology (13%), Rheumatology (13%), Gastroenterology (12%), Pulmonology (11%), Endocrinology (10%). 9% of sites have\\had trials in neurology and 7% – in oncology. 5% of trials at the sites are in the areas of \u0421ovid-19, dermatology and other. The least covered therapeutic areas are hematology (4%), infectious diseases (3%), pediatrics and psychiatry (1% each).<\/span><\/span>\u00a0<\/span><\/span><\/p>\n 93% (210 out of 227) of respondents say they have active clinical trials. Almost 100% of responding CT sites have adapted to work in current circumstances and now they are interested in new CTs, ready for them, fully operational and able to ensure continuous operations in CTs considering current circumstances.<\/span><\/span><\/p>\n